Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

By U. Gatzemeier, A. Płużańska, A. Szczesna, E. Kaukel, J. Roubec, F. De Rosa, J. Milanowski, Hanna Karnicka-Mlodkowski, M. Pesek, P. Serwatowski and 6 more. Journal of Clinical Oncology, 2007

832 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6c0100a0367d591bee46d010d19b94c18575824f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao

In Pulmonary and Respiratory Medicine

1. B. Hughes
2. B. Chan
3. William Pao

Citations in the corpus

• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, background): “one study, there was more rash and diarrhea in the erlotinibcontaining arm.(88) Two large trials investigated the use of gefitinib in”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “The INTACT 1 (48) and INTACT 2 (49) looked at gefitinib whereas the TRIBUTE (50) and TALENT (51) trials used erlotinib.”
• Targeting the EGFR signaling pathway in cancer therapy (2012, background): “Erlotinib, when combined with carboplatin/gemcitabine or cisplatin/paclitaxel in two separate randomized Phase III studies did not produce a survival advantage over chemotherapy alone [89-91].”